7-124824014-TTA-T
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PVS1_Moderate
The NM_015450.3(POT1):c.1851_1852delTA(p.Asp617fs) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000628 in 1,609,030 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.000020 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000067 ( 0 hom. )
Consequence
POT1
NM_015450.3 frameshift
NM_015450.3 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 0.738
Genes affected
POT1 (HGNC:17284): (protection of telomeres 1) This gene is a member of the telombin family and encodes a nuclear protein involved in telomere maintenance. Specifically, this protein functions as a member of a multi-protein complex that binds to the TTAGGG repeats of telomeres, regulating telomere length and protecting chromosome ends from illegitimate recombination, catastrophic chromosome instability, and abnormal chromosome segregation. Increased transcriptional expression of this gene is associated with stomach carcinogenesis and its progression. Alternatively spliced transcript variants have been described. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 2 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. Fraction of 0.0283 CDS is truncated, and there are 0 pathogenic variants in the truncated region.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POT1 | NM_015450.3 | c.1851_1852delTA | p.Asp617fs | frameshift_variant | 19/19 | ENST00000357628.8 | NP_056265.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
POT1 | ENST00000357628.8 | c.1851_1852delTA | p.Asp617fs | frameshift_variant | 19/19 | 2 | NM_015450.3 | ENSP00000350249.3 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152054Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
3
AN:
152054
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000241 AC: 6AN: 248612Hom.: 0 AF XY: 0.0000223 AC XY: 3AN XY: 134472
GnomAD3 exomes
AF:
AC:
6
AN:
248612
Hom.:
AF XY:
AC XY:
3
AN XY:
134472
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000673 AC: 98AN: 1456976Hom.: 0 AF XY: 0.0000566 AC XY: 41AN XY: 724944
GnomAD4 exome
AF:
AC:
98
AN:
1456976
Hom.:
AF XY:
AC XY:
41
AN XY:
724944
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152054Hom.: 0 Cov.: 32 AF XY: 0.0000404 AC XY: 3AN XY: 74268
GnomAD4 genome
AF:
AC:
3
AN:
152054
Hom.:
Cov.:
32
AF XY:
AC XY:
3
AN XY:
74268
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:2Uncertain:3
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Tumor predisposition syndrome 3 Pathogenic:1Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | St. Jude Molecular Pathology, St. Jude Children's Research Hospital | Aug 26, 2022 | The POT1 c.1851_1852del (p.Asp617GlufsTer9) change deletes two nucleotides and causes a frameshift and the creation of a premature stop codon. It is not expected to result in nonsense mediated decay and removes less than 10% of the protein. Functional studies have demonstrated the importance of the C-terminus of POT1 in protein-protein interactions, however studies are needed to determine the effect of this variant (PMID: 28393832; 28393830). This variant has been reported in an individual with a personal and family history of oligodendroglioma (PMID: 25482530) and in an individual with uveal melanoma (PMID: 32907878). This variant has a maximum subpopulation frequency of 0.0062% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 07, 2014 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 21, 2024 | This sequence change creates a premature translational stop signal (p.Asp617Glufs*9) in the POT1 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 18 amino acid(s) of the POT1 protein. This variant is present in population databases (rs758673417, gnomAD 0.004%). This premature translational stop signal has been observed in individual(s) with acute myeloid leukemia, colorectal cancer, head and neck squamous cell carcinoma, oligodendroglioma, and/or uveal and cutaneous melanoma (PMID: 25482530, 27329137, 29625052, 32191290, 32907878, 34193977). This variant is also known as c.1458_1459del. ClinVar contains an entry for this variant (Variation ID: 209095). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 26, 2024 | The c.1851_1852delTA variant, located in coding exon 15 of the POT1 gene, results from a deletion of two nucleotides at nucleotide positions 1851 to 1852, causing a translational frameshift with a predicted alternate stop codon (p.D617Efs*9). Frameshifts are typically deleterious in nature, however, this frameshift occurs at the 3' terminus of POT1, is not expected to trigger nonsense-mediated mRNA decay, and impacts only the last 18 amino acids of the protein. Another alteration, Q623H, located downstream of this frameshift was identified in a familial melanoma case, and has been shown to be important for binding to TPP1 and proper telomere maintenance (Shi J et al. Nat. Genet. 2014 May;46:482-6; Rice C et al. Nat. Commun. 2017 Apr;8:14928). Additionally, internal case control analysis showed a significant association of melanoma and sarcoma in probands heterozygous for c.1851_1852delTA compared to probands with a negative multigene testing panel result (Ambry internal data). Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jun 09, 2023 | Frameshift variant predicted to result in protein truncation as the last 18 amino acids are replaced with 8 different amino acids, although loss-of-function variants have not been reported downstream of this position in the protein; This variant is associated with the following publications: (PMID: 27329137, 25710457, 25482530, 26847028, 32449991, 28393830, 34193977, 29625052, 32987645, 32907878) - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at